Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering
SM Deyev, EN Lebedenko… - Russian chemical …, 2015 - iopscience.iop.org
The review outlines progress and problems in the design of non-natural antibodies for
clinical applications over the past $10 {-} 15\{\text {years}} $. The modular structure of natural …
clinical applications over the past $10 {-} 15\{\text {years}} $. The modular structure of natural …
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives
L Giraudo, L Gammaitoni, M Cangemi, R Rotolo… - …, 2015 - Future Medicine
Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes endowed with
potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic …
potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic …
[HTML][HTML] Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition
F Wei, XX Rong, RY Xie, LT Jia, HY Wang, YJ Qin… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Cancer stem cells (CSCs) are considered to be the root cause for cancer treatment failure.
Thus, there remains an urgent need for more potent and safer therapies against CSCs for …
Thus, there remains an urgent need for more potent and safer therapies against CSCs for …
Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer
C Li, S Liang, C Zhang, Y Liu, M Yang, J Zhang, X Zhi… - Biomaterials, 2015 - Elsevier
Dendritic cells (DCs) have displayed the promising potential in cancer immunity. How to
enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention …
enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention …
Activated T cells armed with bispecific antibodies kill tumor targets
D Bhutani, LG Lum - Current Opinion in Hematology, 2015 - journals.lww.com
Activated T cells armed with bispecific antibodies kill tumo... : Current Opinion in
Hematology Activated T cells armed with bispecific antibodies kill tumor targets : Current …
Hematology Activated T cells armed with bispecific antibodies kill tumor targets : Current …
Неприродные антитела и иммуноконъюгаты с заданными свойствами: оптимизация функций через направленное изменение структуры
СМ Деев, ЕН Лебеденко, ЛЕ Петровская, ДА Долгих… - Успехи химии, 2015 - elibrary.ru
Проанализированы успехи и проблемы в области создания неприродных антител для
клинического применения за последние 10-15 лет. Рассмотрены модульная структура …
клинического применения за последние 10-15 лет. Рассмотрены модульная структура …
Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a …
AR Elia, P Circosta, D Sangiolo, C Bonini… - Human gene …, 2015 - liebertpub.com
Cytokine-induced killer (CIK) cells consist of a heterogeneous population of polyclonal T
lymphocytes displaying NK phenotype and HLA-unrestricted cytotoxic activity against a …
lymphocytes displaying NK phenotype and HLA-unrestricted cytotoxic activity against a …
全身化疗联合DC-CIK 过继免疫治疗中晚期胃癌的临床研究
李井泉， 梁杰雄 - 河北医药, 2015 - cqvip.com
目的研究全身化疗联合DC-CIK 过继免疫对中晚期胃癌的治疗效果. 方法中晚期胃癌患者66 例,
随机分为生物治疗组(n= 34) 和常规治疗组(n= 32). 生物治疗组Ⅱ, Ⅲ 期患者行手术治疗 …
随机分为生物治疗组(n= 34) 和常规治疗组(n= 32). 生物治疗组Ⅱ, Ⅲ 期患者行手术治疗 …
胃癌患者DC-CIK 治疗前后外周血Treg 细胞及相关细胞因子的变化
孙伟红， 魏晓芳， 赵鹏， 李长优， 高岱清 - 中国肿瘤生物治疗杂志, 2015 - cqvip.com
目的: 观察胃癌术后患者DC 联合细胞因子活化的杀伤细胞(cytokin-induced killer, CIK)
治疗前后外周血中Treg 细胞及相关细胞因子水平变化. 方法: 选择2009 年4 月至2013 年12 …
治疗前后外周血中Treg 细胞及相关细胞因子水平变化. 方法: 选择2009 年4 月至2013 年12 …
抗CD133/CD3 双特异性抗体装载的CIK 细胞对高表达CD133 结直肠癌细胞杀伤效应的探讨
吕海燕， 刘传杰， 黄建华 - 中华老年多器官疾病杂志, 2015 - cqvip.com
目的: 探讨抗CD133/CD3 双特异性抗体装载的CIK (BsAb-CIK) 细胞对高表达CD133
结直肠癌细胞的杀伤效应. 方法通过化学偶联制备抗CD133 和抗CD3 的双特异性抗体 …
结直肠癌细胞的杀伤效应. 方法通过化学偶联制备抗CD133 和抗CD3 的双特异性抗体 …